Anaemia in rheumatoid arthritis (RA)
Investigations have suggested that interleukin 1 (IL-1) or tumour necrosis factor (TNF), or both, from monocytes associated with chronic inflammation are responsible for the anaemia of chronic disease. On bone marrow examination anaemia of chronic disease is characterised by the diversion of iron from the erythropoietic compartment into marrow macrophages. This phenomenon is termed failure of iron utilisation.
In this study, CFU-E (colony forming unit erythroid; late red cell precursors) and BFU-E (burst forming unit erythroid; early red cell precursors) stem cells were cultured from 10 normal marrow samples and 12 marrow samples from patients with RA with iron deficiency anaemia and 10 samples from patients with RA with failure of iron utilisation. All patients with RA were anaemic (haemoglobin<100 g/l), Potential accessory or inhibitory cells of erythropoiesis (CD4, CD8, or CD14 positive cells) were removed before culture. Control marrow samples were studied in a similar manner. Normal marrow samples yielded 377 (17) CFU-E and 133 (6) BFU-E (mean (SD)) colonies for each 2x105 light density cells plated. CD4 ablation caused reductions of 62 and 100% in CFU-E and BFU-E colonies respectively. CD14 removal resulted in considerable but lesser reductions of 46% for CFU-E and 25% for BFU-E. In both groups of patients with RA, CFU-E colony numbers were significantly lower than those seen in normal control subjects, 293 (17) for patients with iron deficiency anaemia and 242 (35) for patients with failure of iron utilisation. BFU-E colony numbers were 102 (13) and 108 (20) respectively. In patients with RA, CD4 removal caused a significantly greater loss of CFU-E colonies compared with normal control subjects. Cytolysis of CD14 positive cells caused a reduction in CFU-E colonies in the two RA groups which was similar to that seen in normal subjects. In conclusion, patients with RA seem to have fewer CFU-E progenitors but essentially normal numbers of BFU-E stem cells. Our data suggest a stimulatory role for marrow CD4 and CD14 cells in erythropoiesis in patients with RA. Monocytes-macrophages (CD14 positive) are known to be producers of IL-1 or TNF, or both, however, the predicted increase in the CFU-E colonies on removal of CD14 cells is not seen. Therefore, if IL-1 or TNF, or both, are responsible for the impairment of erythropoiesis in patients with RA, marrow macrophages are unlikely to be the source. Moreover, these results indicate the probability of erythropoietin resistance on the basis of diminished CFU-E colony formation in patients with RA. 
Patients and methods

PATIENT GROUPS AND MARROW SAMPLING
Marrow samples were aspirated from the posterior iliac crests or sterna of patients with RA with either iron deficiency anaemia (12 patients) or failure of iron utilisation (ten patients). Control marrow samples were obtained from ten patients undergoing diagnostic aspiration in whom haemopoiesis was normal and in whom no inflammatory condition was present.
Patients with RA were included in the study if they had anaemia (haemoglobin<100 g/l), no evidence of B-12 or folic acid deficiency, nor of thyroid or renal dysfunction. Patients were excluded if they were receiving cyclophosphamide or azathioprine as these drugs are known to interfere with bone marrow culture. tp<0-001-0003.
were defined as having iron deficiency when no stainable iron was observed in the marrow sample.
CULTURE OF CFU-E AND BFU-E ERYTHROID PRECURSORS
Light density marrow cells were obtained by density centrifugation (sp. gr. Table 2 compares the erythroid colony activity in patients with RA with that in normal subjects. CFU-E levels are significantly impaired in patients with RA with iron deficiency anaemia and failure of iron utilisation (p=0-002 and 0-004 respectively). BFU-E levels are (35) 108 (20) *(IDA) iron deficiency anaemia; (FIU) failure of iron utilisation. slightly, but not significantly, lower in the rheumatoid groups compared with normal subjects. Table 3 shows the effects of cytolysis of potential accessory cells of erythropoiesis from marrow light density cell preparations before culture. In marrow samples from patients with RA and normal subjects removal of CD4 positive cells had a deleterious effect on subsequent CFU-E and BFU-E formation. The reduction in erythroid colony formation was significantly more profound in patients with RA compared with normal subjects following CD4 cell ablation (p<005 and p<0004 for patients with RA with iron deficiency anaemia and failure of iron utilisation compared with normal subjects respectively). CD8 cell cytolysis was found to have a significant effect on each stage of erythropoiesis in the group with failure of iron utilisation. As expected, CD4 cell removal had an especially dramatic effect on BFU-E numbers in all groups. CD14 cell removal was consistently detrimental to CFU-E and BFU-E formation in all groups. Intergroup comparisons showed no difference in the extent of reductions in CFU-E colony formation following CD14 cytolysis. However, the percentage decrease in BFU-E numbers was significantly greater in the group with failure of iron utilisation compared with normal subjects (p<0-014).
The figure shows the effects of selective cytolysis of subpopulations of mononuclear cells on erythropoiesis in the three groups studied.
Discussion
This study shows that the in vitro erythropoietic capacity of marrow from patients with RA is significantly impaired at the CFU-E level compared with normal subjects. CFU-E cells appear at day 4 or 5 of culture and comprise the immediate precursors of pronormoblasts. The more primitive erythroblast colonies (BFU-E) which were enumerated on day 14 of culture are similar in number to those of normal subjects. Previous studies by other workers have shown reduced BFU-E numbers in patients with RA and anaemia of chronic disease compared with non-anaemic subjects. '6 The development of CFU-E from BFU-E stem cells and subsequent differentiation into more mature red cells is dependent on erythropoietin. '7 18 Red cell divisions at the primitive BFU-E stage are dependent on burst promoting activity, a major component of which is interleukin 3 (IL-3).'9 20 Interleukin 3 may also affect later stages of erythroid development. '9 21 The fact that CFU-E rather than BFU-E numbers were significantly decreased in patients with RA suggests that there may be reduced Owing to the important part played by nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of RA, we examined the possible contribution of these drugs to the anaemia of RA by looking at the effect of indomethacin on erythroid colony numbers. Our data (not shown) showed no difference when indomethacin (105 mol/l) was present in culture. It is therefore unlikely that NSAIDs exert a direct inhibitory effect on erythropoiesis.
Our study considers erythropoiesis in RA at two levels of development of red cell precursors, unlike previous in vitro studies which focused on BFU-E stem cells alone." 16 CFU-E stem cells are a critical stage in the marrow response to anaemia as they are highly dependent on erythropoietin. Our data showed a significant impairment of CFU-E formation in RA. This finding leads us to question whether an aberration in either erythropoietin response or production could be contributing in part to the disordered erythropoiesis observed in patients with RA. Previous studies present conflicting evidence about the effectiveness of erythropoietin secretion in active RA.3 34 As we cultured marrow samples from normal subjects and patients with RA with identical amounts of erythropoietin, which had been shown to be sufficient for effective erythropoiesis in normal marrow samples, it is likely that marrow from patients with RA does show a blunted response to erythropoietin at the CFU-E level. As our culture system does not include supraoptimal concentrations of erythropoietin, it is possible that marrow macrophages are further contributing to in vitro levels of erythropoietin. The mechanisms underlying the anaemia of chronic disease are likely to be several and complex. The sequestration of iron by marrow macrophages seen in the failure of iron utilisation must also be a contributory factor in the pathogenesis of anaemia in these patients. In the failure of iron utilisation iron is unavailable for erythropoiesis due to its impaired release from the monocyte-macrophage system to circulating transferrin. Within this system iron is bound to apoferritin for which is has a higher afffmnity than for transferrin. As 
